The age of psychedelic treatment is upon us.
With over 970 million people around the world affected by mental illness, the need for alternative therapies is rising, and fast.
Fortunately, researchers are discovering effective ways to treat patients with mental health disorders (i.e. depression and PTSD), by using psychoactive substances, like ketamine and psilocybin.
What’s more, psychedelic therapy provides patients with greater access to a broader set of solutions, at only a fraction of the cost.
From an investment standpoint, this has helped fuel the industry’s rapid growth.
And as we continue to progress the medical potential of psychedelics, it is likely possible that its use cases evolve beyond the current scope, thus increasing its adoption and consumption in the long run.
Ultimately, this means more interest and investment in the industry, and more patients receiving life-changing treatment.
So, how do you invest?
Well, in this article we’ll explore the fascinating field of psychedelic therapy, as well as one of the most promising businesses in the industry today.
With multiple ketamine clinics across Canada, the world’s top-ranked depression researcher as its CEO, and a proven telemedicine platform, there are few companies of its caliber in this industry.
If you are serious about investing in cutting-edge medicine, like ketamine therapy, then you will want to learn what Braxia Scientific has to offer.
What is Braxia?
Braxia Scientific (Canada: BRAX) (USA: BRAXF) is a dynamic and innovative medical research company changing the game in the mental health field.
With a focus on developing novel drugs and delivery methods for treating mental health disorders, Braxia Scientific is at the forefront of the emerging field of psychedelic medicine.
The company’s mission is to reduce the illness burden of brain-based disorders, such as major depressive disorder, by discovering and commercializing safe and effective treatments that can improve patients’ quality of life.
At the heart of Braxia Scientific’s business is the therapeutic potential of ketamine and other psychedelic substances.
These substances have been shown in clinical studies to have rapid and profound effects on mood and can help people with treatment-resistant depression and other mental health conditions where traditional treatments have failed.
Braxia is working to better understand the composition of these substances and to develop new, innovative delivery methods that can make their use more accessible and effective for its patients.
Braxia’s World-Class Team
One of the things that make Braxia Scientific so special is its team of experts in the field of ketamine and psychedelic medicine.
Led by CEO Dr. Roger McIntyre, a world-renowned psychiatry and mood disorders expert, Braxia is in an unparalleled position as a clinic and drug development company.
With over 25 years of experience, treating more than 100,000 people with depression, Dr. McIntyre’s extensive knowledge and expertise give the Company a unique competitive advantage in developing novel treatments for brain-based disorders.
What’s more, his leadership is proving valuable in other ways as Braxia has been able to attract some of the brightest minds in the field of psychedelic medicine.
- Medical Director, Dr. Joshua Rosenblat, an expert in neuroscience and psychopharmacology, with many years of experience treating hundreds of patients with ketamine.
- Vice President of Operations, Kevin Kratiuk, who oversees Braxia’s Health Clinics under its wholly-owned subsidiary Canadian Rapid Treatment Center of Excellence (CRTCE).
- Chief Information Officer, Jason Wolkove, a seasoned tech executive with more than 20 years of growing complex technical product, sales, and service teams and building SaaS software systems.
Together, this group of talented individuals, as well as other members, are driving Braxia Scientific’s innovative approach to mental health research and creating new and effective treatments for patients suffering from brain-based disorders.
In total, the Company has more than 100 medical professionals treating patients.
With their expertise, dedication, and passion, they are changing the game in mental health research and making a real difference in people’s lives.
How KetaMD Changes the Game for Mental Health Patients
To increase access and affordability to patients, Braxia launched its end-to-end telemedicine platform KetaMD.
KetaMD is an innovative approach that allows patients to receive ketamine-assisted therapy from the comfort of their homes, while still receiving the same high-quality care and supervision they would in a clinical setting.
The platform works by consulting with the patient and shipping ketamine medication to their home.
Then, a patient connects with a licensed healthcare provider who will oversee the therapy session remotely and guide them through the treatment via the KetaMD app.
In doing so, KetaMD adds significant value to Braxia’s business by enabling its healthcare providers to reach a larger patient population, without the need for a physical clinic.
This makes the therapy sessions more convenient and comfortable for patients as they no longer are required to travel to a designated location.
In turn, patients receive the same high-quality care, as they would at an in-person clinic, especially since the platform is backed by Braxia Scientific’s rigorous research and clinical expertise.
As such, KetaMD offers patients a new opportunity that is more convenient and effective, thus representing a major step forward in Braxia’s mental health treatments.
Braxia’s In-Person Clinics
To supplement its KetaMD platform, Braxia also owns five clinics in Eastern Canada, specializing in ketamine treatments for various mood disorders.
Under its fully owned subsidiary, Braxia Health Clinics, Braxia offers rapid-onset treatments to aid patients suffering from treatment-resistant conditions like depression and bipolar disorder.
Braxia is also looking to expand its business by providing its services across 38 states in the United States; the Company is exploring opportunities in Europe as well.
So far, this model has proven quite successful as it generates the bulk of the company’s revenues to date.
For example, in its fiscal 2023, Braxia Clinics reported a 26.2% YoY increase in treatment volumes (3,516 from 2,785 treatments) and increased demand across all of its five clinics–The new Ottawa clinic experienced an 87.2% YoY jump in treatment volumes.
By having in-person clinics, Braxia offers patients a personalized experience intended to be welcoming and supportive, while also providing quality care from its experienced healthcare professionals.
Moreover, these clinics provide a high level of safety and supervision, meaning that patients can be comfortable knowing that they are receiving top-notch treatment during their transformative experiences.
All-in-all, Braxia’s clinics, coupled with its KetaMD platform, makes Braxia Scientific’s business a powerful resource for anyone looking to improve their mental health and well-being.
Braxia’s Research Advantage
While its KetaMD platform and treatment clinics are certainly impressive, what truly differentiates Braxia Scientific is its research capabilities.
For starters, Braxia is Canada’s only organization with its own clinical infrastructure, IP, and patient access with clinics delivering ketamine treatments.
This vertically-integrated ecosystem allows Braxia to deliver the best patient care while fostering innovation and clinical excellence.
Even more impressive, Braxia conducts all its research in-house, unlike its competitors who rely on third parties.
This approach has helped them reach Phase 2 studies in just 18-24 months, compared to the typical 3-5 years.
And if you need more proof of their research prowess, Braxia’s team has already published over 750 peer-reviewed articles on psychedelic therapy.
From a development standpoint, Braxia is proving quite successful as it became one of the first-ever Canadian companies to dose eligible individuals, suffering from treatment-resistant depression, with multi-dose psilocybin in 2021.
In terms of its overall clinical trial portfolio, the Company has four studies in its pipeline meant to address patients dealing with bipolar disorder and treatment-resistant MDD.
Eventually, Braxia intends to partner with larger pharmaceutical companies that will acquire the Phase 2 trials and manage their development into the future.
As one of the only psychedelic clinic and drug development companies with R&D capabilities of this caliber, Braxia Scientific is in an excellent position to innovate and develop for many years to come.
This puts them in a league of their own, creating a massive competitive advantage that will be difficult for competitors to replicate.
Why Psychedelic Therapy?
Mental illness plays a very detrimental role in the world we live in today, affecting the lives of hundreds of millions of people.
In fact, Americans spent around $280 billion on mental health services in 2020 alone.
And with one in five Americans affected by mental health in a given year, the economic burden of brain disorders is becoming an increasingly important issue
What’s more, up to 75% of patients do not respond sufficiently to existing conventional treatments.
This harsh reality is even more alarming when you discover that the U.S. is expected to be short millions of mental healthcare providers by 2025.
So, given the dire situation, it is clear that new, more accessible, and innovative solutions, like Braxia’s KetaMD telemed platform are needed.
Fortunately, the Company is more than capable of alleviating the burden by providing patients with its ketamine-assisted therapies.
And with its vertically integrated ecosystem proving quite effective in this market, it seems like Braxia’s solutions are bound to be quite valuable in the coming years.
Why You Should Consider Braxia
Braxia Scientific (Canada: BRAX) (USA: BRAXF) is at the forefront of a rapidly expanding field of research and development in the use of psychedelic medicines to treat mental health disorders.
With a team of experienced professionals and a dedication to cutting-edge research, Braxia is well-positioned to be a leader in this exciting and promising field.
The Company’s focus on developing evidence-based treatments, working closely with patients and healthcare providers, and partnering with leading organizations, speaks to their commitment to advancing the science and clinical application of psychedelic medicine.
As the demand for effective and innovative mental health treatments continues to grow, Braxia’s dedication to providing safe, effective, and innovative treatments offers hope to millions of individuals struggling with mental health disorders.
Overall, we believe that Braxia Scientific is poised to make a significant impact in the years to come, and we look forward to following its progress with great interest.
To learn more about Braxia Scientific (Canada: BRAX) (USA: BRAXF), please visit its website below.
|BRAXIA SCIENTIFIC (Canada: BRAX.CN)(USA: BRAXF)
We are not brokers, investment, or financial advisers; you should not rely on the information herein as investment advice. If you are seeking personalized investment advice, please contact a qualified and registered broker, investment adviser, or financial adviser. You should not make any investment decisions based on our communications. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Edge Investments and its owners currently hold shares in Braxia stock and are compensated by Braxia for Investor Relations Services. Edge Investments and its owners reserve the right to buy and sell shares in Braxia without further notice, which may impact the share price. Please do your own research before investing, including reading the companies’ public filings, press releases, and risk disclosures. The company provided information in this profile, extracted from public filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it. The commentary and opinions in this article are our own, so please do your own research.
Copyright ©️ 2023 Edge Investments, All rights reserved.